HK Stock Market Move | GIANT BIOGENE (02367) rises over 7% again, CCTV conducts in-depth investigation of GIANT BIOGENE. Institutions are optimistic about the company's new products and new business.

Giant Biogene (02367) has risen over 7%, up 5.8% as of the time of writing to 31.38 Hong Kong dollars, with a trading volume of 1.89 billion Hong Kong dollars. On the news front, CCTV Finance and CCTV News released a in-depth video on April 14, with the CCTV host Chen Weihong visiting Giant Biogene to decode the complete process of replicating collagen from its genetic sequence to large-scale production. The video also unveiled the latest breakthrough in transdermal technology for recombinant collagen, showcasing China's strong biotechnology capabilities moving from the laboratory to the consumer market. Changjiang pointed out that the company's revenue and profits may be under short-term pressure in the second half of 2025, but cost control has shown resilience. Considering that the company's two types of medical devices "Recombinant Type I 1 subtype collagen freeze-dried fiber" and "Recombinant Type I 1 subtype collagen and hyaluronic acid sodium composite solution products" have been successively approved, demonstrating its continued leading innovative capabilities and strategic strength. The subsequent commercialization of two more medical beauty products and the launch of several new cosmetic products are worth looking forward to, and it is recommended to continue monitoring the progress of the company's new products and new business.